• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Etamsilate for the treatment of herpes virus infections. The local administration of etamsilate has produced good clinical results in the short term in the treatment of virus infections, preferably in herpes caused by infection of the simplex virus that occurs on the mucous and epithelial surfaces, such as genital herpes and herpetic stromal keratitis, and particularly in cold sores. This hemostatic drug can provide a new approach to the treatment of these diseases. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2734584A1
    申请号:ES201830489
    申请日:2018-05-22
    公开日:2019-12-10
    发明作者:Sánchez Pedro Cuevas；Gallego Guillermo Giménez
    申请人:Dobecure S L；
    IPC主号:
    专利说明:

    [0001]
    [0002]
    [0003]
    [0004] FIELD OF THE INVENTION
    [0005] The invention describes the use of ethamsylate for the manufacture of a medicament for the treatment of viral infections that employ heparan sulfate for cell penetration, more specifically for the treatment of patients suffering from herpes simplex viral infection that occurs on any mucosal surface. or epithelial such as genital herpes and herpetic stromal keratitis, and particularly for the treatment of cold sores.
    [0006]
    [0007] The use of ethamsylate as a therapeutic agent may be as a pharmaceutically acceptable salt or solvate thereof,
    [0008]
    [0009] BACKGROUND OF THE INVENTION
    [0010] The herpes simplex 1 virus (HSV-1) is the cause of a lifelong infection that affects 50-90% of the world's population. In addition to causing skin lesions, HSV-1 is the leading cause of blindness as a result of recurrent corneal infection (Vet Microbiol 2002, 86:17). The main ocular manifestations of herpetic infection are keratitis, blepharitis, conjunctivitis, uveitis, dry eye and retinitis (Arq Bras Ofhalmol 2013; 17: 129-132). HSV-1 is a neurotropic member of the herpes / alpha virus family. Primary infection typically occurs after inoculation of epithelial surfaces of the mucosa, using heparan sulfate for cell penetration. During the initial infection, the virions access the sensory nerve fibers and are transported to the neural cell bodies in the trigeminal ganglia where the HSV-1 establishes a latent infection (J Clin Microbiol 2003, 41:84; Sex Transm Infect 2005; 81: 103). HSV-1 is the leading cause of facial lesions (mouth, lips and eyes) in humans.
    [0011] The usual treatment of HSV-1 infections generally depends on a combination of antiviral and anti-inflammatory drugs such as corticosteroids, the latter need to be administered for prolonged periods, a circumstance that can cause unwanted side effects. In addition, the massive use of acyclovir and similar nucleosides has led to the emergence of HSV-1 strains resistant to these medications. Therefore, it is an urgent need, the development of alternative and more effective therapies for the control of HSV-1 infections.
    [0012]
    [0013] The inventors have surprisingly found that the local administration of etamsylate in viral infections that use heparan sulfate for cell penetration shows clinical benefits, something that also happens with viral infections located in mucous membranes and epithelia and particularly in cold sores.
    [0014]
    [0015] DESCRIPTION OF THE INVENTION
    [0016] Local administration of the compound can be in the form of creams, gels, ointments, dispersions, solid rods, emulsions and microemulsions that can be formulated according to conventional methods using suitable excipients. The vehicles and solvents that can be used are water, Ringer's solution and isotonic sodium chloride solution.
    [0017]
    [0018] Generally, the dose required to provide an effective amount of the compound and composition, which can be adjusted by someone with sufficient skill, will vary depending on the extent of the disease and the frequency of treatment.
    [0019]
    [0020] The main object of the present invention is directed to the treatment or prevention of the disease described in this document. In addition, the present invention can be used for the treatment or prevention of cold sores and other viral infections that employ heparan sulfate for cell penetration.
    [0021] Throughout this document, the following terms, unless otherwise indicated, shall be understood to have the following meanings.
    [0022]
    [0023] "Patient" refers to the human being and includes both women and men.
    [0024] "Treat", "treating" or "treatment" refers to the use of the compounds of the invention from a prophylactic point of view, to prevent the symptoms of the disease, or therapeutic, to improve an existing condition.
    [0025]
    [0026] "Therapeutic agent" includes any therapeutic agent that can be used to treat or prevent the disease described below. The concept of therapeutic agent includes, but is not limited to, antiviral, anti-inflammatory and similar compounds. The concept of therapeutic agent includes pharmaceutically acceptable salts.
    [0027]
    [0028] Except if otherwise indicated, all technical and scientific elements used in this specification have the sense commonly understood by a person with average knowledge in the field to which this invention belongs. When this invention is put into practice, the methods and materials that can be used will be similar or equivalent to those described in this specification.
    [0029]
    [0030] Throughout the description and its claims, the word "represent" and its variants are not intended to exclude other technical characteristics, additives, components or steps. For those skilled in the art, other objects, advantages and features of the invention can be deduced from the description and practical use of the invention.
    [0031]
    [0032] EXAMPLE OF THE INVENTION
    [0033] The following example without being limiting describes the use of the present invention.
    [0034]
    [0035] Efficacy of etamsylate in the treatment of cold sores
    [0036] A 44-year-old woman had an injury caused by cold sores in her right lip corner (Figure 1). After valuing the different treatment options, the patient chose to treat topically by administering ethamsylate and signed an informed consent. The patient administered ethamsylate (OM Pharma Switzerland) in a 12% glycerin solution three times daily until day 4. After the first day of treatment the patient was pain free and after the fourth day of treatment, Herpetic lesion had healed without any apparent cosmetic disturbance (Figure 1). The patient did not declare recurrent episodes of herpetic lesion in her right labial commissure after several months of treatment. Although the exact mechanism of action of ethamsylate is unknown, we can suggest that this drug works by blocking heparan sulfate and, consequently, prevents the penetration of the virus into the cytoplasm.
    [0037]
    [0038] EXPLANATION OF THE FIGURES
    [0039] As a complement to the present description and in order to help make the features of the invention more easily understandable, and according to a personalized practical example, said description is accompanied by a set of images that are an integral part thereof, which by way of illustration and without limitation are presented below.
    [0040]
    [0041] Figure 1. Shows the effects of ethamsylate in the treatment of cold sores. Appearance of the lesion of cold sores prior to treatment by local application of ethamsylate (A), at two days (B) and at four days (C). The red circle indicates the right lip corner, where cold sores and their evolution (B) and (C) appeared.
    权利要求:
    Claims (3)
    [1]
    1- The use of etamsylate or solvate thereof or its salts in any pharmaceutical form, as a therapeutic agent, in the manufacture of a medicament for the treatment of viral infections using heparan sulfate for cell penetration.
    [2]
    2. - The use of ethamsylate according to claim 1 in viral infections such as herpes simplex virus infections that occur on mucous and epithelial surfaces such as genital herpes and stromal keratitis.
    [3]
    3. - The use of ethamsylate according to claim 1 in viral infections of cold sores.
    类似技术:
    公开号 | 公开日 | 专利标题
    Kaufman2000|Treatment of viral diseases of the cornea and external eye
    ES2813649T3|2021-03-24|Orally administrable pharmaceutical composition for the prevention or treatment of dry eye syndrome, comprising rebamipide or a prodrug thereof
    JPH06100446A|1994-04-12|Asthma treatment method using |-alpha -fluoromethyl- histidine and ester thereof
    Penna et al.1986|Oxybuprocaine keratopathy: a preventable disease.
    ES2649730T3|2018-01-15|Cranial distribution of pharmaceutical compounds
    SK284464B6|2005-04-01|Use of compound chosen from the group consisting of vitamin E and esters thereof for the manufacture of a medicament for treatment of mucosal pathologies
    JP5030553B2|2012-09-19|Pharmaceuticals for treating dry mice and / or salivary secretion disorders
    ES2734584B2|2020-05-04|ETHAMSILATE FOR THE TREATMENT OF HERPES VIRUS INFECTIONS
    Margolis et al.1990|Treatment of ocular disease in eczema herpeticum
    US8450330B2|2013-05-28|Pharmaceutical acceptable composition containing non-steroidal anti-inflammatory drug and local anesthetics
    Wood et al.1988|Suprofen treatment of contact lens-associated giant papillary conjunctivitis
    BR112019002655A2|2019-07-02|compound, synthesis intermediate, use and neuromodulatory pharmaceutical composition
    EP3167881B1|2019-08-28|Locally administered ethamsylate as a medicament
    TW202031263A|2020-09-01|Ophthalmic composition for preventing deterioration of soft contact lenses
    JP2019533731A|2019-11-21|CBD and copaxone combination therapy
    JP2004307354A|2004-11-04|Method for treating amyotrophic lateral sclerosis using melatonin
    Takeshita1996|Bilateral herpes simplex virus keratitis in a patient with pemphigus vulgaris
    Lam et al.1993|Iris crystals in chronic iridocyclitis.
    SANTEN et al.2015|Risk Management Plan
    Sandmeyer et al.2016|Diagnostic Ophthalmology
    RU2720993C2|2020-05-15|Pyrrolidone-carboxylic acid | for ophthalmic use
    Capella et al.2011|Limbal stem cell deficiency following multiple intravitreal injections
    Gundersen1935|Convalescent blood for herpes zoster
    Kötter et al.2004|Human recombinant interferon-α2a | for the treatment of Behçet’s disease with sight-threatening retinal vasculitis
    Gans1950|Aureomycin in treatment of otitic and ophthalmic herpes zoster
    同族专利:
    公开号 | 公开日
    EP3572079A1|2019-11-27|
    EP3572079B1|2021-09-08|
    ES2734584B2|2020-05-04|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    CN1861062A|2006-06-14|2006-11-15|王德昌|Medicine composition used for fish or other aquatic livings and its prepn. method|
    CN101530405A|2009-04-14|2009-09-16|何诚|Citric acid and compound citric acid application in pharmacy|
    CN102600120A|2012-01-04|2012-07-25|中国农业大学|Application of cinnamic acid in preparation of drugs for preventing and treating livestock and poultry virus infection|
    EP3167881A1|2015-10-19|2017-05-17|Cuevas Sánchez, Pedro|Locally administered ethamsylate as a medicament|
    CN106963729A|2017-04-16|2017-07-21|李孝国|It is a kind of to be used to prevent pharmaceutical preparation of operative hemorrhage and preparation method thereof|
    WO2001013910A2|1999-08-25|2001-03-01|Massachusetts Institute Of Technology|Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry|
    US20170364630A1|2014-12-05|2017-12-21|Vanderbilt University|Identification of cellular antimicrobial drug tablets through interactome analysis|
    法律状态:
    2019-12-10| BA2A| Patent application published|Ref document number: 2734584 Country of ref document: ES Kind code of ref document: A1 Effective date: 20191210 |
    2020-05-04| FG2A| Definitive protection|Ref document number: 2734584 Country of ref document: ES Kind code of ref document: B2 Effective date: 20200504 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201830489A|ES2734584B2|2018-05-22|2018-05-22|ETHAMSILATE FOR THE TREATMENT OF HERPES VIRUS INFECTIONS|ES201830489A| ES2734584B2|2018-05-22|2018-05-22|ETHAMSILATE FOR THE TREATMENT OF HERPES VIRUS INFECTIONS|
    EP18382389.7A| EP3572079B1|2018-05-22|2018-06-04|Etamsylate for treatment of herpes virus infections|
    [返回顶部]